Abstract: A mounting device for an elongate member, comprising: an elongate housing having an elongate axis; an internal passageway passing through the elongate housing parallel to the elongate axis; an elongate sleeve located within the internal passageway and being configured for longitudinal movement along the passageway; a plurality of ball-receiving recesses in the wall of the internal passageway, each recess having a ball-guiding surface inclined to the longitudinal axis; a plurality of apertures in the sleeve; a ball located in each of the ball-receiving recesses and engaged with a respective aperture in the sleeve, the balls and the apertures being configured to allow the balls to project partially through the apertures but to prevent balls from passing through; biasing means configured to bias the sleeve in a direction to urge the balls to project radially inwardly through their respective apertures in the sleeve and into the internal passageway.

Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, inside the package. A nonlimiting example of the package can be a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Optionally, the package further comprises a bag, a blister, a pouch or any other vessel. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained. The said pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist is suitable for sterilization (such as for surface and/or terminal sterilization) with sterilization gas residuals being minimal and/or lower than required by ISO 10993-7.

Abstract: A liquid formulation of an ophthalmic drug in a pre-filled pharmaceutical package, for example a syringe, cartridge, vial or any other vessel made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. A blister, a pouch, a bag, a tray or a tub may encompass as a secondary packaging the syringe, vial, cartridge, tube or any other vessel. The package is suitable for sterilization (e.g., surface and/or terminal sterilization) with sterilization gas residuals being minimal and/or lower than required by ISO 10993-7; and/or the stability of the ophthalmic drug is maintained, during a prolonged time period following the sterilization. The sterilization gas may be EO, propylene oxide, chlorine dioxide, nitrogen dioxide, or vaporized hydrogen peroxide (VHP), among others.

Abstract: A mounting device for an elongate member, comprising: an elongate housing having an elongate axis; an internal passageway passing through the elongate housing parallel to the elongate axis; an elongate sleeve located within the internal passageway and being configured for longitudinal movement along the passageway; a plurality of ball-receiving recesses in the wall of the internal passageway, each recess having a ball-guiding surface inclined to the longitudinal axis; a plurality of apertures in the sleeve; a ball located in each of the ball-receiving recesses and engaged with a respective aperture in the sleeve, the balls and the apertures being configured to allow the balls to project partially through the apertures but to prevent balls from passing through; biasing means configured to bias the sleeve in a direction to urge the balls to project radially inwardly through their respective apertures in the sleeve and into the internal passageway.

Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.

Abstract: An example welding torch neck adapter includes: an electrically conductive body configured to detachably attach to a handle assembly of a consumable electrode-fed welding torch on a first portion of the conductive body and configured to detachably attach to a neck of the welding torch on a second portion of the conductive body to secure the neck to the handle assembly; and a guide tube positioned within the conductive body and configured to support a first consumable wire liner in alignment with a liner lock of a second consumable wire liner.

Abstract: A liquid formulation of an ophthalmic drug in a pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer.

Abstract: A liquid formulation of an ophthalmic drug in a pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer.

Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.

Abstract: A vehicle vision system including an isolation block configured to compress under pressure, a rigid block on an interface surface of the isolation block configured to distribute pressure across the interface surface of the isolation block, the rigid block including a first protrusion extending away from the interface surface and having a cavity, and a camera embedded within the cavity and configured to capture video images.

Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.

Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.

Abstract: Various techniques are provided to efficiently detect the position and angular velocity of an object relative to a compact radar system including a transmitter antenna array and a receiver antenna array. In one example, a method includes repeatedly scanning a transmitter antenna array and a receiver antenna array of an object sensing system through a plurality of designated transmitter and receiver channels over a period of time to generate a time series of measured channel responses corresponding to each one of the designated channels, determining a time series of directional vectors to or from an object scanned by at least one of the designated channels, and/or a corresponding time series of average phase differences, based, at least in part, on the time series of measured channel responses, and determining an angular velocity of the object from the time series of directional vectors and/or the corresponding time series of average phase differences.

Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, in a pre-filled pharmaceutical package, for example a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained.

Abstract: An electrostatic painting device capable of reducing any AC or electromagnetic emissions when the device is powered on is provided. The emissions affect electronic components present during painting of various objects or even when the device is powered on. The electromagnetic induction into the conductive circuit elements in turn induces voltages and currents, which potentially harm the micro-electronic circuits. One such device includes a choke between a fluid tip and a high voltage source of the device to reduce these emissions. The voltage source may include at least one capacitor which supplies the AC emissions representing electromagnetic emissions risk during the discharge of paint from the device. The choke connected to the voltage source substantially reduces the emissions involved during the paint discharge, while allowing the discharge of electrons, thereby imparting negative DC charge to the paint and the workpiece, and preventing damage to electronic circuits during the process.

Abstract: An electrostatic painting device capable of reducing any AC or electromagnetic emissions when the device is powered on is provided. The emissions affect electronic components present during painting of various objects or even when the device is powered on. The electromagnetic induction into the conductive circuit elements in turn induces voltages and currents, which potentially harm the micro-electronic circuits. One such device includes a choke between a fluid tip and a high voltage source of the device to reduce these emissions. The voltage source may include at least one capacitor which supplies the AC emissions representing electromagnetic emissions risk during the discharge of paint from the device. The choke connected to the voltage source substantially reduces the emissions involved during the paint discharge, while allowing the discharge of electrons, thereby imparting negative DC charge to the paint and the workpiece, and preventing damage to electronic circuits during the process.

Abstract: Various techniques are provided to efficiently detect the position and angular velocity of an object relative to a compact radar system including a transmitter antenna array and a receiver antenna array. In one example, a method includes repeatedly scanning a transmitter antenna array and a receiver antenna array of an object sensing system through a plurality of designated transmitter and receiver channels over a period of time to generate a time series of measured channel responses corresponding to each one of the designated channels, determining a time series of directional vectors to or from an object scanned by at least one of the designated channels, and/or a corresponding time series of average phase differences, based, at least in part, on the time series of measured channel responses, and determining an angular velocity of the object from the time series of directional vectors and/or the corresponding time series of average phase differences.

Abstract: Various techniques are provided to efficiently detect the position and angular velocity of an object relative to a compact radar system including a transmitter antenna array and a receiver antenna array. In one example, a method includes repeatedly scanning a transmitter antenna array and a receiver antenna array of an object sensing system through a plurality of designated transmitter and receiver channels over a period of time to generate a time series of measured channel responses corresponding to each one of the designated channels, determining a time series of directional vectors to or from an object scanned by at least one of the designated channels, and/or a corresponding time series of average phase differences, based, at least in part, on the time series of measured channel responses, and determining an angular velocity of the object from the time series of directional vectors and/or the corresponding time series of average phase differences.

Abstract: A vehicle vision system including an isolation block configured to compress under pressure, a rigid block on an interface surface of the isolation block configured to distribute pressure across the interface surface of the isolation block, the rigid block including a first protrusion extending away from the interface surface and having a cavity, and a camera embedded within the cavity and configured to capture video images.

Abstract: A pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist, for example Ranibizumab, inside the package. A nonlimiting example of the package can be a syringe, cartridge, or vial, made in part or in whole of a thermoplastic polymer, coated on the interior with a tie coating or layer, a barrier coating or layer, a pH protective coating or layer, and optionally a lubricity coating or layer. Optionally, the package further comprises a bag, a blister, a pouch or any other vessel. Stability performance of the VEGF-antagonist packaged in the coated COP vessel comparable to or better than glass was obtained. The said pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist is suitable for sterilization (such as for surface and/or terminal sterilization) with sterilization gas residuals being minimal and/or lower than required by ISO 10993-7.